Cadila Healthcare, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA), a leading generic pharmaceutical company in the United States, have finalized an agreement with Upsher-Smith Laboratories, to settle all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules. Under the terms of the agreement, Upsher-Smith grants Zydus a license to market Zydus' generic version of Qudexy XR beginning on March 19, 2020, or earlier under certain circumstances.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
